← Back to searchRecruitingRecruiting
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
NCT07300969 · Draig Therapeutics Ltd
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder (MDD)
About this study
The purpose of this study is to compare DT-101 and placebo in adult participants with MDD. The study will also evaluate how safe and well tolerated the study drug is. The clinical study staff will check participants' suitability to take part in the clinical research study by performing physical and neurological examinations, obtaining blood and urine samples, conducting clinical assessments and reviewing medical and treatment history. These tests and assessments will continue throughout the study with the purpose of checking the participants' ongoing suitability and to collect data to analyze the effect that DT-101 may have on their depression symptoms. Participants will also have blood samples taken to allow analysis of how DT-101 is absorbed and used by the body (PK sampling), some blood samples may be retained in order to perform future research that may be useful when looking at whether genetics affects how a person responds to DT-101 (PGx sampling)
Eligibility criteria
Inclusion Criteria:
* The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent
* Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent.
* Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022).
Exclusion Criteria:
* Pregnant or breastfeeding or plans to become pregnant during the study.
* Unstable medical condition or unstable chronic disease.
* Significant neurological abnormality.
* History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening.
* History of seizure.
* In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.
Study design
Enrollment target: 300 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2025-12-16
Estimated completion: 2027-08
Last updated: 2026-03-17
Interventions
Drug: DT-101Drug: DT-101Drug: Placebo
Primary outcomes
- • Change from baseline in total Montgomery Åsberg depression rating scale (MADRS) score, at Day 42 (from enrollment to day 42)
Sponsor
Draig Therapeutics Ltd · industry
Contacts & investigators
ContactChief Medical Officer · contact · info@draigtherapeutics.com · +44(0)2920028450
All locations (24)
Draig Clinical SiteRecruiting
Bentonville, Arkansas, United States
Draig Clinical SiteRecruiting
Little Rock, Arkansas, United States
Draig Clinical SiteRecruiting
Oceanside, California, United States
Draig Clinical SiteRecruiting
San Diego, California, United States
Draig Clinical SiteRecruiting
Torrance, California, United States
Draig Clinical SiteRecruiting
Miami, Florida, United States
Draig Clinical SiteRecruiting
New Port Richey, Florida, United States
Draig Clinical SiteNot Yet Recruiting
Orlando, Florida, United States
Draig Clinical SiteRecruiting
Atlanta, Georgia, United States
Draig Clinical SiteRecruiting
Decatur, Georgia, United States
Draig Clinical SiteRecruiting
Gaithersburg, Maryland, United States
Draig Clinical SiteRecruiting
Watertown, Massachusetts, United States
Draig Clinical SiteRecruiting
Flowood, Mississippi, United States
Draig Clinical SiteRecruiting
Las Vegas, Nevada, United States
Draig Clinical SiteRecruiting
Marlton, New Jersey, United States
Draig Clinical SiteRecruiting
New York, New York, United States
Draig Clinical SiteRecruiting
Media, Pennsylvania, United States
Draig Clinical SiteNot Yet Recruiting
Austin, Texas, United States
Draig Clinical SiteRecruiting
DeSoto, Texas, United States
Draig Clinical SiteRecruiting
Richardson, Texas, United States
Draig Clinical SiteRecruiting
Wichita Falls, Texas, United States
Draig Clinical SiteRecruiting
Bellevue, Washington, United States
Draig Clinical SiteNot Yet Recruiting
Glasgow, United Kingdom
Draig Clinical SiteRecruiting
Oxford, United Kingdom